When did NURIX THERAPEUTICS INC (NRIX) report earnings last quarter?
NURIX THERAPEUTICS INC (NRIX) last reported earnings on 1/28/2026.
NASDAQ:NRIX • US67080M1036
Past quarterly earnings results for NURIX THERAPEUTICS INC (NRIX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.82 | -0.89 | 7.66% | -9.33% | 13.577M | 14.595M | -6.97% | 2.21% |
| Q3 2025 | -1.03 | -0.86 | -20.05% | -53.73% | 7.894M | 17.07M | -53.76% | -37.29% |
| Q2 2025 | -0.52 | -0.74 | 30.11% | 26.76% | 44.056M | 17.349M | 153.94% | 264.34% |
| Q1 2025 | -0.67 | -0.78 | 13.97% | 11.84% | 18.453M | 12.968M | 42.30% | 11.26% |
| Q4 2024 | -0.75 | -0.69 | -8.65% | 2.60% | 13.284M | 13.116M | 1.28% | -12.37% |
| Q3 2024 | -0.67 | -0.72 | 7.58% | 1.47% | 12.588M | 12.284M | 2.47% | -31.84% |
| Q2 2024 | -0.71 | -0.65 | -9.62% | -57.78% | 12.092M | 22.547M | -46.37% | -60.58% |
| Q1 2024 | -0.76 | -0.82 | 7.10% | -1.33% | 16.585M | 16.977M | -2.31% | 30.69% |
| Q4 2023 | -0.77 | -0.58 | -32.44% | 11.49% | 15.159M | 22.707M | -33.24% | 123.58% |
| Q3 2023 | -0.68 | -0.77 | 11.80% | 24.44% | 18.467M | 17.572M | 5.09% | 71.15% |
| Q2 2023 | -0.45 | -0.57 | 21.22% | 55.45% | 30.676M | 26.74M | 14.72% | 168.38% |
| Q1 2023 | -0.75 | -0.89 | 15.29% | 21.05% | 12.69M | 11.088M | 14.45% | 31.91% |
| Q4 2022 | -0.87 | -0.80 | -8.12% | -2.35% | 6.78M | 17.515M | -61.29% | -8.38% |
| Q3 2022 | -0.90 | -1.00 | 9.55% | -38.46% | 10.79M | 12.325M | -12.45% | 5.27% |
| Q2 2022 | -1.01 | -1.01 | -0.40% | -68.33% | 11.43M | 10.71M | 6.72% | 61.21% |
| Q1 2022 | -0.95 | -0.89 | -6.36% | -50.79% | 9.62M | 9.459M | 1.70% | 92.02% |
| Q4 2021 | -0.85 | -0.71 | -20.12% | -66.67% | 7.4M | 13.459M | -45.02% | 10.61% |
| Q3 2021 | -0.65 | -0.64 | -0.92% | -10.17% | 10.25M | 8.715M | 17.61% | 150.61% |
| Q2 2021 | -0.60 | -0.55 | -8.26% | - | 7.09M | 8.391M | -15.50% | 69.62% |
| Q1 2021 | -0.63 | -0.47 | -34.86% | - | 5.01M | 8.099M | -38.14% | 75.17% |
| Q4 2020 | -0.51 | -0.55 | 7.06% | - | 6.69M | 4.024M | 66.25% | - |
| Q3 2020 | -0.59 | -0.42 | -40.23% | - | 4.09M | 6.464M | -36.73% | - |
| Q2 2020 | - | - | 4.18M | - | - | |||
| Q1 2020 | - | - | 2.86M | - | - |
Notes
NURIX THERAPEUTICS INC (NRIX) last reported earnings on 1/28/2026.
NURIX THERAPEUTICS INC (NRIX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NURIX THERAPEUTICS INC (NRIX) has beaten EPS estimates in 3 out of 4 releases.